Parkinson's disease

News

AC Immune's chief executive Dr Andrea Pfeifer

AC Immune says Parkinson's drug slows progression

AC Immune's active immunotherapy study backs up the alpha-synuclein hypothesis in Parkinson's disease, after disappointments in earlier trials.

News

Merck partners Valo on $3bn, AI-based Parkinson's project

Merck has teamed up with Valo Health on a project to apply AI to the discovery of novel drug targets and drugs for Parkinson's.

News

UK starts 'largest-ever' trial of possible Parkinson's drugs

UK researchers have started a large-scale trial to test a battery of potential Parkinson's drugs to see if they can slow down disease progression.

R&D

pharmaphorum podcast Episode 209a, Gene Mack

Allosteric small molecule therapies in PD, with Gene Mack

pharmaphorum looks back to a conversation with Gain Therapeutics' CEO Gene Mack earlier in the year, on research in the Parkinson's disease space.

News

Bayer starts pivotal Parkinson's cell therapy trial

Bayer's much-anticipated stem cell therapy for Parkinson's disease is gathering momentum, with dosing in phase 3 trials now underway.

News

NRG raises £50m to start trials of Parkinson's, ALS drug

NRG Therapeutics' oversubscribed Series B will fund first-in-human trials of a drug targeting mitochondrial dysfunction in neurodegenerative diseases.

AC Immune says Parkinson's drug slows progression

Merck partners Valo on $3bn, AI-based Parkinson's project

UK starts 'largest-ever' trial of possible Parkinson's drugs

Allosteric small molecule therapies in PD, with Gene Mack

Bayer starts pivotal Parkinson's cell therapy trial

NRG raises £50m to start trials of Parkinson's, ALS drug

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

Parkinson's disease

Editor's Picks